News Archives

February 6, 2023

ASH 2022: Dr. Matthew Davids on the Contribution of Obinutuzumab to Acalabrutinib Therapy in Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Leukemia (CLL / SLL)

Our own Dr. Brian Koffman interviewed Dr. Matthew Davids, Associate Director of the Center for Chronic Lymphocytic Leukemia (CLL) at Dana-Farber Cancer Institute. They discussed the results of a new study looking at whether combining the anti-CD20 monoclonal antibody obinutuzumab with the BTK inhibitor acalabrutinib provided any additional survival

February 3, 2023

CLL Society’s COVID-19 Update for the Week of February 6, 2023

Here is your February 6, 2023 weekly summary of what has been happening this past week in the United States.

February 2, 2023

USA Today Links the Immunocompromised to CLL Society’s COVID-19 Action Plan

In their 1/28/2023 article: Weak immune system? Government offers advice to help at-risk people avoid COVID-19 infections in the wake of the FDA’s withdrawal of Evusheld’s emergency authorization as it was ineffective for over 90% of the active SARS-CoV-2 variants of concerns, USA Today urges the immunocompromised to have

January 30, 2023

CLL Society Organizes Joint Effort Urging Government Agencies to Focus on Continued COVID-19 Protections for the Immunocompromised

In light of the FDA’s announcements regarding the discontinuation of Emergency Use Authorization for both Evusheld and Bebtelovimab, CLL Society and eight other patient advocacy organizations sent a letter to federal officials requesting them to immediately undertake thirteen specific actions that would help protect the estimated seven million Americans

January 30, 2023

CLL Society’s COVID-19 Update for the Week of January 30, 2023

Here is your weekly summary of what has been happening this past week of January 30, 2023 in the United States.

January 30, 2023

FDA Approves Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma

On 1/27/23 Loxo@Lilly announced the Federal Drug Administration (FDA)’s accelerated approval of pirtobrutinib in adult patients with relapsed or refractory mantle cell lymphoma (MCL) following at least 2 lines of systemic therapy, including a BTK inhibitor.

January 30, 2023

FDA Announces Evusheld is Not Currently Authorized for Emergency Use in the U.S.

As of 1/26/23, Evusheld (tixagevimab co-packaged with cilgavimab) is no longer available as Pre-Exposure Prophylaxis (PrEP) in the United States. That decision was made because as the virus continued to mutate, now over 90% of SARS-CoV-2 variants of concerns (VOC) circulating in the U.S. are no longer believed to

January 24, 2023

ASH 2022: Dr. Clare Sun Explains Her Research on Sudden Death Among a Small Number of Chronic Lymphocytic Leukemia (CLL) Patients Using Ibrutinib

Dr. Sun was interviewed by Dr. Brian Koffman, a physician, CLL patient, and executive vice president and chief medical officer of CLL Society, at the ASH 2022 meeting in New Orleans. In the interview, she elaborates on the research results and recommendations on how patients can avoid cardiac issues

January 24, 2023

ASH 2022: Dr. John Seymour on the Adverse Event Burden of Acalabrutinib vs. Ibrutinib in Patients with Chronic Lymphocytic Leukemia (CLL)

In this interview, our own Dr. Brian Koffman interviewed Dr. John Seymour, Director of the Department of Hematology at Peter MacCallum Cancer Centre & Royal Melbourne Hospital in Melbourne, Australia. They discussed the latest updates to the safety data from the ELEVATE R/R study, which was the first clinical

Cookie	Duration	Description
cookielawinfo-checkbox-analytics	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional	11 months	The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy	11 months	The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.

News

ASH 2022: Dr. Matthew Davids on the Contribution of Obinutuzumab to Acalabrutinib Therapy in Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Leukemia (CLL / SLL)

CLL Society’s COVID-19 Update for the Week of February 6, 2023

USA Today Links the Immunocompromised to CLL Society’s COVID-19 Action Plan

CLL Society Organizes Joint Effort Urging Government Agencies to Focus on Continued COVID-19 Protections for the Immunocompromised

CLL Society’s COVID-19 Update for the Week of January 30, 2023

FDA Approves Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma

FDA Announces Evusheld is Not Currently Authorized for Emergency Use in the U.S.

ASH 2022: Dr. Clare Sun Explains Her Research on Sudden Death Among a Small Number of Chronic Lymphocytic Leukemia (CLL) Patients Using Ibrutinib

ASH 2022: Dr. John Seymour on the Adverse Event Burden of Acalabrutinib vs. Ibrutinib in Patients with Chronic Lymphocytic Leukemia (CLL)

CLL SOCIETY FAST FIND

QUICK LINKS

ABOUT CLL SOCIETY

CONTACT